BioCentury
BioCentury
ARTICLE | Clinical News

ImmunoGen down on Phase III ovarian cancer miss

Brian Moy
March 1, 2019 8:29 PM UTC


Access this Article
Request a Trial
Purchase This Article
Log in

BCIQ Company Profiles

ImmunoGen Inc.

BCIQ Target Profiles

Folate receptor 1 (FOLR1) (FR-alpha) (FOLR)

BCIQ Company Profiles

ImmunoGen Inc.

BCIQ Target Profiles

Folate receptor 1 (FOLR1) (FR-alpha) (FOLR)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Cookie Policy
California Privacy Rights
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
LinkedInTwitterRSS
BioCentury
© 2022 BioCentury Inc. All Rights Reserved.
Copyright © 2022 BioCentury Inc. All Rights Reserved.
LinkedInTwitterRSS